For additional information regarding sites, contact 844-687-8522
New York, 10012, United States
NCT Number: NCT04186403
This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2 / Phase 3
New York, 10012, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered as tablets.
Other names: Rexulti, OPC-34712
Time frame: Signing of ICF up to 30 days post last dose of study drug (up to approximately 16 weeks)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with an onset date on or after the start of open-label treatment. The severity of AEs was graded on a 3-point scale: 1=Mild (Discomfort noticed, but no disruption to daily activity), 2=Moderate (Discomfort sufficient to reduce or affect normal daily activity), and 3=Severe (Inability to work or perform normal daily activity).
Time frame: Screening up to Week 12
Potentially clinically significant ECG abnormalities included rate: Bradycardia (vent <=50 beats per minute [bpm] and decrease >=15 bpm); Rhythm: Sinus bradycardia (<=50 bpm and decrease >=15 bpm), absence during baseline and presence of ventricular premature beat post baseline; ST/T morphology: Absence at baseline and presence of symmetrical T-wave inversion post baseline.
Time frame: Screening up to Week 12
Potentially clinically significant vital sign abnormalities included: Heart rate standing in bpm (<50 bpm and decrease >=15 bpm, >120 bpm and increase >=15 bpm); Weight in kilograms (kgs) (decrease >=7%, increase >=7%).
Time frame: Screening up to Week 12
Potentially clinically significant laboratory abnormalities included serum chemistry: Prolactin >upper limit of normal (ULN) (nanograms per millilitre [ng/ml] in males and females), fasting glucose ≥100 (milligrams per decilitre [mg/dl]), fasting high-density lipoprotein (HDL) cholesterol <40 (men)/ <50 (women) (mg/dl), fasting low-density lipoprotein (LDL) cholesterol ≥160 (mg/dl), fasting cholesterol ≥240 (mg/dl), fasting triglycerides ≥150 (mg/dl); Creatine phosphokinase (CPK)/renal: Creatine kinase >3xULN (units per litre [U/l]), creatinine ≥2.0 (mg/dl), urea nitrogen ≥30 (mg/dl).
Time frame: Baseline and Week 12
The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.
Time frame: Baseline and Week 12
The AIMS scale consists of 10 items describing symptoms of dyskinesia: Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) (for item 10, no awareness) to 4 (severe condition) (for item 10, awareness, severe distress). AIMS total score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.
Time frame: Baseline and Week 12
The BARS consists of 4 items related to akathisia: Objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The fourth item, global clinical evaluation was rated on a 6-point scale, with a score range of 0 (absence of symptoms) to 5 (severe akathisia). Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
Time frame: Baseline up to Week 12
C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04130958
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial DetailsNCT06005129
Borderline Personality Disorder, Mental Disorders
Lexington, Kentucky, United States
View Trial DetailsNCT06406972
Behavior, Behavioral Symptoms
Lund, Skåne County, Sweden
View Trial DetailsNCT05356013
Borderline Personality Disorder, Mental Disorders
Chicago, Illinois, United States
View Trial Details